Thrombolytic therapy in the eighties.
Verstraete
M
M
Collen
D
D
D000215:Acylation; D000595:Amino Acid Sequence; D000818:Animals; D000933:Antifibrinolytic Agents; D004789:Enzyme Activation; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006706:Homeostasis; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010958:Plasminogen / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D011487:Protein Conformation; D011655:Pulmonary Embolism / Q000188:drug therapy; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D013300:Streptokinase / Q000378:metabolism / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D000979:alpha-2-Antiplasmin; C037742:plasmin-plasmin inhibitor complex; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator